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1. Introduction
Autism spectrum disorders (ASDs) are neurodevelopmental diseases characterized by
repetitive, stereotyped behavior and maldevelopment of social and language skills. Classical
autism, Asperger syndrome and pervasive development disorder-not otherwise specified
(PDD-NOS) are the most commonly diagnosed ASDs. There are also a significant number of
cases that are considered idiopathic because the etiology is unclear (Gillis and Rouleau, 2011).
The incidence of ASDs has increased substantially in the past twenty years, growing by as
much as 5-10 fold; although, the approximate 4:1 ratio of affected males to females has been
relatively constant (Kadesjö et al., 1999). Some of this increase has likely been driven by shifting
diagnostic criteria, heightened awareness and improved diagnostic techniques (Levy et al.,
2007). However, some of this increase could be attributable to an authentic increase in the
frequency of ASDs. The factors fueling this increase remain unclear and the precise causes of
ASDs remain unknown (Stoltenberg et al., 2010). Although its basis is thought to be multifac‐
torial, ASDs are known to have a heritable component (Hu et al., 2006). The inheritance patterns
can to some extent be explained by typical genetic processes but, especially in light of studies
noting discordance among monozygotic twins, this is unlikely to be the whole story (Ptak and
Petronis, 2010). Substantial scientific evidence is emerging suggesting that epigenetic influen‐
ces may be partly responsible for the development of ASDs.
2. Epigenetic protein-DNA interactions: proteins mediating epigenetic
signaling
2.1. Mecp2 and the frontal cortex
Methyl CpG binding protein 2 (Mecp2) is an epigenetic regulator required for development
of neuronal synaptic contacts (Luikenhuis et al., 2004) that is thought to function mainly as a
gene silencing molecule (Chahrour et al., 2008). The Mecp2 gene is located on the q arm of the
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X chromosome and is subject to X-inactivation (Cohen et al., 2008). The Mecp2 mechanism
involves binding to methylated DNA (Yasui et al., 2007) and, after binding, complexing with
histone deacetylase-1 (HDAC1). HDAC1 is responsible for removing acetyl groups from
histones; this removal causes the chromatin to condense and this suppresses gene transcription
at the gene promoter site. Mecp2 is also purported to be an activator of some genes (Mehler,
2008) and, although it is not clear whether the role of Mecp2 in ASDs is dependent on its role
as a gene silencer or promoter, there appear to be strong associations between decreased
expression of Mecp2 and ASDs.
Decreased expression of Mecp2 in frontal cortex and fusiform gyrus (Nagarajan et al., 2006)
-  the  latter  associated  with  neural  processing  of  face  recognition  (LaSalle  et  al.,  2001;
Pelphrey et al., 2004) - has been reported. The Mecp2 gene on the X chromosome and all
males actively express one X chromosome. Hence, aberrant methylation patterns of autistic
males  (the  predominant  sex  affected  by  ASDs)  cannot  be  counteracted  by  a  second  X
chromosome, as occurs in females.  Aberrant methylation of  the 5'  portion of  the Mecp2
regulatory region has been reported for brain samples from males affected by ASDs and,
as expected, there is an inverse correlation between promoter region methylation and Mecp2
expression. There is a well-established relationship between a missense mutation of Mecp2
and Rett  syndrome,  a  pervasive  developmental  disorder  of  females  exhibiting  ASD-like
behaviors (O’Conner et al., 2009).
3. Epigenetic DNA-protein interactions
3.1. Protein kinase c beta and the temporal lobe
Downregulation of the gene for protein kinase C beta (PRKCB1) in the temporal lobe is
reported to be correlated with ASDs (Lintas et al., 2009). Phosphorylation of histone H3 at
threonine 6  (H3T6)  by PRKCB1 appears  to prevent  lysine-specific  demethylase-1 (LSD1)
from demethylating H3K4 during androgen receptor-dependent gene activation (Metzger
et al., 2010). Consequently, downregulation of PRKCB1 could play a role in the predomi‐
nance of male ASD patients. Further, this downregulation may impact deep temporal lobe
(limbic system) synaptogenesis  and consequently preferentially sensitize males (who are
generally exposed to higher fetal androgen concentrations than females) to the environmen‐
tal stressors thought to be involved in the development of ASDs.
3.2. The oxytocin receptor and hypermethylation
Generally,  females  lack  androgen-facilitated  arousal  inputs  to  the  amygdala  and might,
therefore, be protected from the development of ASDs by high fetal levels of estrogens and
oxytocin  (Pfaff  et  al.,  2011).  A  role  for  an  oxytocin  receptor  polymorphism  in  ASDs  is
reported (Wu et al., 2005; Liu et al., 2010) and aberrant DNA methylation in the promot‐
er region of the oxytocin receptor gene has been observed after acute psychosocial stress
(Unternaehrer et al., 2012). Epigenetic dysregulation of the oxytocin receptor gene (OXTR)
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has been implicated in the etiology of ASDs (Jacob et al., 2007) and oxytocin, together with
vasopressin, has also been shown to have socialization functions (Gouin et al., 2010). A link
between oxytocin and ASDs in humans (Insel, 1992) and in knockout mice is also suggest‐
ed by  the  decreased memory and face  recognition  abilities  which are  commonly  found
among ASD patients  (Ferguson et  al.,  2000;  Takayanagi  et  al.,  2005)  and also  adversely
impact  socialization.  It  is  noteworthy that  OXTR-knockout  decrements  in  social  interac‐
tions appear to be sex-specific (Sun et al., 2008).
These findings suggest that any defect of the oxytocin pathway, including a deficiency of
oxytocin receptors, has the potential to contribute to the development of ASDs. A diminish‐
ed number of oxytocin receptors can have a variety of causes, including both genomic and
epigenetic. A study involving a family in which the mother had a hemizygous deletion of
the OXTR gene, noted that the mother passed down the deletion to one of her sons, but
not the other; however, both sons were diagnosed with autism and it turned out that the
promoter  region  of  the  OXTR  gene  of  the  affected  sibling  without  the  deletion  was
hypermethylated (Gregory et al., 2009). Prior studies had identified two CpG island regions
of the OXTR gene that,  as a consequence of variable methylation, seem to be associated
with differential OXTR expression in liver and myometrium (Kimura et al., 2003). The first
CpG island overlaps with exons 1, 2 and 3 of the OXTR gene and the second CpG island
was localized to the third intron. The second CpG island, within intron 3, was found to be
heavily methylated in all three family members studied. The other CpG island -- overlap‐
ping  exons  1,2  and  3  --  was  found  to  be  methylated  differently  in  each  of  the  family
members; specifically, the affected sibling without the deletion showed significantly more
methylation than his brother or mother at three sites within the intron. This hypermethyla‐
tion occurred at locations that have previously been shown to impact OXTR expression.
Since both siblings were autistic in spite of the fact that one had a genomic deletion and
the  other  displayed  hypermethylated  promoter  regions,  this  study  demonstrates  that
epigenetic  and  genetic  mechanisms  can  have  equivalent  effects  on  phenotype.  Further‐
more,  this  study  showed  that  five  differentially  methylated  CpG  islands  which  were
examined in  a  group of  20  autistic  and 20  phenotypically  normal  individuals  exhibited
significantly greater methylation at several of the examined loci. These observations were
made  in  both  blood  and  cerebral  cortex  samples.  Additionally,  low  levels  of  OXTR
expression  were  found  to  be  associated  with  increased  methylation  at  a  statistically
significant level. This finding strengthens the idea that promoter region methylation causes
gene silencing.  Moreover,  when the data were stratified by sex,  two of  the loci  showed
significant differences in methylation for males only, implying that the different frequen‐
cies of autism in males and females might be driven by epigenetic mechanisms.
3.3. Bcl-2 and apoptosis
Bcl-2 (B-cell lymphoma 2) is a protein regulator of apoptosis (Tsujimo et al., 1984) and it s gene
has been linked to ASDs (Glantz et al., 2006). Decreased expression of Bcl-2 has been shown
in cerebellum and frontal cortex of subjects diagnosed with ASDs (Fatemi et al., 2001; Fatemi
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and Halt, 2001), and lymphoblastoid cell lines from sets of monozygotic twins discordant for
ASDs.
3.4. RORA and oxidative stress
A novel hypothesis suggests that ASDs may develop from epigenetic dysregulation of the
retinoic acid-related orphan receptor alpha (RORA), a regulator of circadian rhythm and
neuroprotection from oxidative stress and inflammation, is reported (Akashi and Takumi,
2005; Boukhtouche et al., 2006). The Bcl-2 and RORA hypotheses are similar in that both
depend on the idea that oxidative stress plays a key role in some instances of apoptosis.
The RORA hypothesis is supported by reports that oxidative stress and inflammation are
increased in  patients  diagnosed with  ASDs (Pardo et  al.,  2005;  Chauhan and Chauhan,
2006).  Differences  in  RORA  gene  promoter  region  methylation  and  protein  product
expression  is  reported  for  some  subjects  diagnosed  with  ASDs  and  their  (non-twin)
unaffected siblings (Nguyen et  al.,  2010).  Furthermore,  decreased RORA expression was
found only in the ASD subjects with severe language impairment.
3.5. Beta-catenin, estradiol and lithium
Estrogens are important for sex-related differentiation of the brain and it is likely that brain
estrogen  levels  are  increased  in  subjects  diagnosed  with  ASDs  (MacLusky  et  al.,  1987).
Estrogens, being steroid hormones, and their receptors - including estrogen receptor alpha
(ERα) - are located in the nucleus and in the cytosol of target cells. One of the targets of
cytosolic ERα is GSK3B, which is known to complex with β-catenin in the degradation of
β-catenin. ERα activation by estradiol is reported to release β-catenin from this complex,
thereby increasing β-catenin availability (Cardona-Gomez et al., 2004). An increase in the
cytosolic concentration of estrogens is thought to result in increases in cytosolic and nuclear
β-catenin during critical  periods of prenatal  and neonatal  development during which β-
catenin  binding  to  the  LEC/TCF  promoter  has  positive  effects  on  Wnt  pathway  gene
transcription. Such increased transcription in the Wnt pathway is strongly associated with
the development of ASDs. The effect of ERα is to cause the dissociation of β-catenin from
a complex whose integral  members include the proteins  GSK3β,  axin and adenomatous
polyposis coli tumor suppressor (APC). GSK3β, axin and APC are negative regulators of
the Wnt signaling pathway and the complex requires all of these constituents to initiate the
destruction of β-catenin. The absence or downregulation of any of these components may
increase the availability of cytosolic β-catenin, and consequently the various knock-in effects
discussed previously  -  increased nuclear  β-catenin with greater  Wnt  pathway transcrip‐
tion. Lithium, used mostly as a mood stabilizing drug, exerts an inhibitory effect on GSK3β
both directly and indirectly, by interrupting the dephosphorylation of phospo-GSK3β (Jope,
2003). In either case, the effect is the same, and also the same as that of increased estro‐
gen levels; i.e., the complex responsible for initiating the degradation of β-catenin is made
nonfunctional, and the concentration of cytosolic β-catenin increases.
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3.6. SHANK3 and the neurexin-neuroligin pathway
SHANK3 is a scaffolding protein in the neurexin-neuroligin pathway that interacts with
synaptic proteins. Recent research suggests that copy number variations or mutations of either
of these proteins may be associated with the development of ASDs (Liu et al., 2013). It appears
that epigenetic mechanisms are used to control the expression of this gene. Five CpG islands
in the SHANK3 gene (the post-translational methylation of which determines gene expression)
and one specific locus - CpG island 2 - appear to particularly impact tissue SHANK expression
(Beri et al., 2007). The SHANK3 gene is well conserved between humans and rodents and
neonatal expression of certain SHANK3 transcripts in mice is known to temporarily decrease
methylation of CpG island 2 after birth (Uchino and Waga, 2013). These findings suggest that
the expression of SHANK3 (and thus its effect on the development of ASDs) is regulated by
epigenetic mechanisms, though this connection has yet to be directly established in humans.
Additionally, two genes responsible for the production of cell adhesion molecules in this
pathway, NLGN3 and NLGN4, have also been associated with the development of ASDs (Liu
et al., 2013). However, epigenetic regulation of these genes are, at this time, unproven (Yasuda
et al., 2011).
3.7. IGF-2 and the cerebellum
Disruption of cerebellum cytoarchitecture with loss of Purkinje cells, effects that could have a
negative impact on cerebellum development and postmortem cerebellum weight, has been
described in subjects diagnosed with ASDs (Whitney et al., 2009). Insulin like growth factor-2
(IGF-2) is the product of a paternally imprinted gene, the allele-specific expression of which is
regulated by DNA methylation. DNA methylation at a key transcriptional repressor (CTCF2)
is shown to be correlated with cerebellum weight. Paradoxically, DNA methylation at CTCF3
of the maternally-inherited allele also appears to be associated with an increase in cerebellum
weight (Pidsley et al., 2012).
3.8. Neurotrophins
Contemporary thinking has seized upon neurotrophins (proteins tasked with promoting the
development, and, later, survival of neurons) as potentially important factors in the later
development of ASDs. Neutrophins are growth factors whose prenatal presence (or absence)
might affect neurogenesis in such a way as to make the later development more or less likely.
In particular, a recent investigation focused on the role of three neurotrophic factors -- brain
derived neurotrophic factor (BDNF), neurotophin-4 (NT4) and the immunosuppressive
cytokine transforming growth factor beta (TGF-β) - in the development of ASDs (Nickl-
Jockschat and Michel, 2011). The results, which were based on analysis of dried blood spot
samples of neonates later diagnosed with ASDs and frequency-matched controls, suggest a
role for each of studied neurotrophins: neonates with BDNF and TGF-β concentrations in the
bottom decile were more likely to be diagnosed with ASDs, and eventual ASD neonates were
less likely to have a NT4 concentration in the top decile (Abdallah et al., 2013). In spite of the
authors' conspicuously cautious concluding remarks, their finding may have far reaching
implications (Pareja-Galeano et al., 2013). BDNF has also been implicated in the etiology of a
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variety of neurological and psychiatric conditions - such as Alzheimer's and Huntington - that
are posited to be involved in dysfunctional CNS synapse development. The results of the
neurotrophin study are in line with this idea. The BDNF gene has been linked to early life
stressors and their concomitant brain responses and behavioral outcomes, which suggests than
an aberrant BDNF gene - or aberrant epigenetic regulation of that gene - might compromise
the brain's advanced paternal capacity to mount a robust response to early life stressors,
including those that were linked to ASDs in our earlier discussion. Furthermore, BDNF has
been proposed as a link mediating interactions between genes, environmental conditions,
synaptic plasticity and apoptosis and some research suggests that environmental and social
conditions early in life may affect the epigenetic regulation of BDNF (Balaratnasingam and
Janca, 2012). This points to a (somewhat speculative) mechanism for the development of ASDs:
Adverse perinatal conditions alter the epigenetic regulation of BDNF which in turn limits the
young brain's ability to properly respond to its adverse environment which then makes the
development of ASDs more likely. These ideas may also be the first steps towards a strategy
to reduce the ASD frequency. Since the higher concentrations of BDNF (as well as NT4 and
TGF-β) are associated with decreased frequency of ASDs, promoting the upregulation of those
proteins may be protective. Mouse models have shown that music exposure can increase the
brain BDNF concentration in mice, however this finding is yet to be extended to the perinatal
human context (Angelucci et al., 2007). Similarly, controlled physical exercise demonstrably
increases BDNF concentrations in rats (Lee et al., 2013). Either, or both, of these approaches
may be useful in encouraging a perinatal environment that minimizes the eventual develop‐
ment of ASDs.
3.9. The locus coeruleus-noradrenergic system and fever
The study of epigenetics encompasses more than differential methylation and acetylation
of  gene promoter  regions.  Indeed,  any mechanism that  affects  gene expression,  without
altering the genetic code, may be considered an epigenetic mechanism. This broader view
of  epigenetics  can  help  explain  a  curious,  but  common,  observation:  Autistic  children
consistently exhibit diminished ASD symptoms when febrile (Curran et al., 2007). This effect
of  fever  appears  to  have  nothing to  do  with  methylation,  gene  silencing or  promotion.
Furthermore, there is no reason to suspect that the appearance of fever would result in the
addition of methyl groups to particular portions of the genome. However, one hypothe‐
sis  argues  that  febrile  episodes  temporarily  modify  the  functional  integrity  of  the  locus
coeruleus-norandrenergic (LC-NA) system, the dysregulation of which has been implicat‐
ed as a proximate cause of ASD symptoms (Mehler and Purpura, 2009). This hypothesis is
plausible, particularly in view of the functions of the LC-NA system. LC is in the pontine
tegmentum and is notable for containing the most widely spread efferent projections of any
nucleus  in  the  brain  (Foote  et  al.,  1983).  Most  of  the  norepinephrine  in  the  brain  is
transported by these neurons.  This property of the LC-NA system is significant because
distributed neural networks - those that are associated with the ability to make behavori‐
al adaptations to environmental changes and that tend to be disrupted in ASD patients -
are modulated by the LC-NA system. Indeed, the LC-NA system is also implicated in several
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other neurodegenerative and psychiatric disorders. The key point is that autism is frequent‐
ly associated with dysregulation of the LC-NA system and fever also affects the LC-NA
system. Moreover, febrile symptoms are typically induced by bacterial lipopolysaccharide
and symptoms in the brain are, in turn, mediated by norepinephrine (Linthorst et al., 1995).
Because most of the brain’s norepinephrine is released from LC neurons, it is reasonable
to think that the LC-NA system is somehow altered in the febrile state, especially since LC
neurons are known to exhibit  extremely synchronized activity.  Consequently,  fever may
induce a change in LC-NA system functions that diminishes ASD symptoms. The discov‐
ery  of  this  relationship  between ASD symptoms and LC-NA functions  implies  that  the
neural networks of autistic patients are not irreparably damaged but, rather, are function‐
ally intact. Theoretically, these findings suggest that fever-related changes in the brain might
provide  a  useful  experimental  model  for  the  development  of  drugs  and  other  targeted
therapies  for  ASDs.  Moreover,  the  existence  of  this  relationship between fever  and LC-
NA system functions points to a broader view of the concept of epigenetic mechanisms.
Indeed, epigenetic effects may be thought of as relatively static, such as in the case of DNA
methylation, or dynamic such as in the case represented by the connection between fever
and the LC-NA system. This difference is roughly analogous to that between chronic and
acute symptoms of a disease. A fully effective treatment of ASDs might require targeting
both of the aforementioned types of epigenetic causative mechanisms.
4. Role of maternal hypomethylation
Development of the LC-NA system seems to be strongly impacted by prenatal events,
reflecting the importance of environment-gene interactions. Maternal hypomethylation is an
epigenetic mechanism that has effects on the intrauterine environment and which, in turn, may
predispose fetuses to developing ASDs. Greater prevalence of ASDs is reported in children
whose mothers were exposed to hurricanes or tropical storms during gestation (Beversdorf et
al., 2005) and if the accompanying stress causes dysregulation in a distributed neural network
such as the LC-NA system, it could result in a predilection for ASDs. Thus, epigenetic
influences on the maternal genome could alter the intrauterine environment such that the
probability of the offspring developing ASDs is increased or decreased. DNA hypomethylation
linked to variants in the maternal folate pathway have been linked to aberrant fetal develop‐
ment (Foote et al., 1983; Linthorst et al., 1995). Because folate is the primary one carbon donor
in methylation reactions, epigenetic dysregulation of the folate pathway should provide
insight into the availability of methylation precursors and also the extent of genomic methyl‐
ation in mothers of unaffected children compared to mothers of children diagnosed with ASDs.
Indeed, mothers of children diagnosed with ASDs often exhibit aberrant DNA methylation
(James et al., 2008). Moreover, mothers of children diagnosed with ASDs also exhibit signifi‐
cantly lower levels of methylfolate and methionine - essential precursors for DNA methylation
- than their non-ASD counterparts. In addition, levels of the methylation-inhibiting proteins
S-adenosylmethoinine, adenosine and homocysteine were all elevated in autism mothers. S-
adenosylmethonine (SAM) is the primary methyl donor for the DNA methyltransferase
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reaction, which produces S-adenosylhomocysteine (SAH) and methylated DNA. Because SAM
and SAH are linked by the transferase reaction the SAM/SAH ratio is generally considered to
be a good indicator of DNA methylation potential. Mothers of children diagnosed with ASDs
often exhibit lower SAM/SAH ratios than control groups, indicative of a diminished capacity
for methylation. Furthermore, the DNA of the mothers of children diagnosed with ASDs
appears to be less methylated than that of mothers of unaffected children; the ratio of 5-
methylcytosine to total cytosine - a measure of overall genomic methylation - was significantly
lower in the mothers of autistic children (James et al., 2008). Taken together, this evidence
strongly suggests that hypomethylation of maternal DNA may be linked to ASDs. However,
the significance of these findings about the influences of epigenetics on the development of
autism is not entirely clear.
5. Role of advanced paternal age in autism
Advanced paternal age is strongly associated with a variety of childhood conditions (Goriely
et al., 2013). The relationship between advanced paternal age and autism is especially well-
established. Large-scale studies have shown that advanced paternal age may increase the
offspring's risk of developing an ASDs by as many as six fold. Despite such a striking effect,
the specific mechanism underlying the relationship between older fathers and autistic children
is not precisely clear. It seems likely that the link is at least partly explained by the effect of
paternal age on germ cell integrity; a greater number of sperm divisions (and therefore
opportunities for duplication errors) occur as paternal age increases, and the disparity between
paternal and maternal germ line divisions widens. Of course, advanced paternal age may
covary with a number other factors that may exert an effect on ASD frequency, not the least
of which is maternal age. It's worth noting that none of these proposed mechanisms are
mutually exclusive; in fact, it is entirely possible that the observed effects are the consequence
of combination of a number of factors.
Some of these factors may have an epigenetic nexus. Rat model studies have demonstrated the
germ cells of older rats tended to have changes in chromatin packaging, and consequently
decreased gene integrity. In one notable study, sensitivity to oxidative treatment was used as
a proxy for resilience and integrity of chromosomal packaging. Four-month-old and 21-month-
old Brown Norway rats were systematically exposed to L-buthionine-[S,R]-sulphoximine
(BSO) (a drug with well-known glutathione depleting properties) and hydrogen peroxide. The
chromatin from spermatozoa of the younger rats demonstrated less nuclear chromomycin A3
penetration, decreased thiol oxidation, fewer DNA breaks and reduced tendency to dissociate
from acridine orange - all indications of more fragile genetic material (Zubkova and Robaire,
2006). Researchers have also conducted systematic searches for age-related global and gene-
specific methylation patterns. Using restriction landmark genomic scanning to determine
methylation patterns of CpG islands, one study detected a ribosomal DNA locus the methyl‐
ation of which is correlated with age; interestingly, the methylation of all studied single copy
CpG island sequences were independent of age (Oakes et al., 2003). Together, these results
suggest the presence of a direct effect of paternal age on the epigenome.
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The science underlying the effect paternal age on genetic integrity is well-known and relatively
straightforward; the hundreds of replications that spermatogonial undergo allow for greater
numbers of point mutations, chromosomal breakages and copy number alterations than are
typically observed in maternal cell lines (Perrin et al., 2007). However, the pervasive nature of
the genetic effects of advanced paternal age somewhat complicates the evaluation of its
epigenetic impacts. Consequently, separating the genetic and epigenetic effects can be delicate
work. The evidence required to make such a determination must be biochemical; merely noting
an association between increased paternal age and frequency of ASDs is insufficient to account
for possibly confounding genetic effects. On the other hand, we know that dysregulation of
imprinted genes, which as noted earlier often occur in clusters that are regulated by imprinting
centers, is associated with altered brain development, and, notably, neurocognitive conditions
such as autism. Recent studies have bridged this gap by demonstrating that advanced paternal
age may increase the likelihood of the epigenetic dysregulation of the imprinting centers.
Specifically, mouse models have indicated that the epigenetic loss of suppression of particular
genes occurs more frequently in older mice than younger mice. Two examples of specific genes
are illustrative (Bennett-Baker et al., 2003). The first, copper-transporting ATPase 1 (Atp7a), is
located on the X chromosome and is consequently subject to X-linked inactivation. Quantita‐
tive comparison of RNA transcripts from young and old mice (2 and 24 months of age,
respectively) have shown significantly less consistent X-inactivation among the transcripts
from the older mice. This, in turn, suggests that, to some extent, the Atp7a gene of the older
mice is hypomethylated as compared to the younger cohort. When we recall that the methyl‐
ation resulting in gene inactivation is heritable, it follows that the offspring of older mice are
more likely to inherit hypomethylated, and thus not inactivated, paternal alleles. A similar
epigenetic mechanism has been demonstrated for the insulin growth factor 2 gene (Igf2).
Unlike Atp7a, Igf2 is subject to genomic imprinting. As we've noted previously, epigenetic
effects may manifest through manipulation of the imprinting process. It has also been
demonstrated that older mice cohorts produce RNA transcripts from silenced alleles more
frequently than their younger counterparts. Here again, this alteration of the imprinting
process - mediated through changes in methylation patterns - is a heritable epigenetic change
that results as a consequence of advanced paternal age. Further, we're beginning to see similar
results in studies of human subjects. Most notably, a study of the cord blood of a group of
Chinese Han newborns (approximately 20% of whom had non-imprinted Igf2 genes) found
that although no measured maternal factor was statistically correlated with loss of imprinting,
this epigenetic alteration was associated with increased paternal age (Dai et al., 2007). These
studies comprise fairly compelling evidence of the effect exerted by advanced paternal age on
the epigenome. It follows closely that these mechanisms have the potential to result in the
passing of genetic material to ASD-susceptible offspring.
6. Nutritional factors
The ultimate effect of nutritional imbalances depends greatly on the developmental period
during which the imbalance occurs. Different organs have critical developmental stages, and
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the time point at which they are compromised will predispose individuals to specific diseases.
Also, depending on the function of the gene, epigenetic modifications that occur during
development may not be expressed until later in life. While the majority of studies implicate
prenatal and perinatal periods as critical time windows, some research has shown that
nutritional intake during adulthood can also affect the epigenome.
Genetic polymorphisms of cytochrome P450 enzymes have been linked to ASDs, specifically
the cytochrome P450 family 27 subfamily B gene (CYP27B1), which is essential for proper
vitamin D metabolism. Epigenetic regulation of cytochrome P450 genes for hydroxylation and
activation of vitamin D in has been shown in prostate cancer cells (Luo et al., 2010). Vitamin
D is important for neuronal growth and neurodevelopment, and defects in its metabolism or
deficiency have also been implicated in ASDs (Currenti, 2010). Mutations of Mecp2 associated
with impaired methylation are known to be associated with autism and a related neurological
disorder, Rett syndrome. One component of Rett syndrome is abnormal bone formation caused
by abnormal vitamin D metabolism, which is associated with epigenetic dysregulation of
cytochrome P450 genes (O'Connor et al., 2009) which could be a conceptual model for
epigenetic interactions between Mecp2, vitamin D and cytochrome P450 genes (Currenti et al.,
2010). As noted earlier, abnormal folic acid metabolism may play a role in the decreased
capacity for methylation and DNA hypomethylation associated with significantly higher-
than-normal levels of plasma homocysteine, adenosine, and SAH in mothers of subjects
diagnosed with ASDs (James et al., 2010). Indeed, nutritional factors such as folic acid appear
to be protectors against the epigenetic dysregulation associated with ASDs. DNA methylation,
the most established epigenetic gene regulation, is a one-carbon transfer dependent mecha‐
nism requiring folate, choline, betaine and other B vitamins (Anderson et al., 2012) and it is,
therefore, not surprising that folic acid supplementation in pregnancy appears to be protective
against the development of ASDs (Surén et al., 2013). Changes in autism-related behaviors are
reported to be strongly associated with vitamin-supplementation associated changes in
plasma levels of biotin and vitamin K (Adams et al., 2011). Although biotin is a known cofactor
in bioavailability of methyl groups for DNA methylation, a vitamin K-related epigenetic
mechanism has not been described.
7. Toxic factors
7.1. Exposure to valproic acid
Valproic acid (VPA) is a therapeutic anticonvulsant and mood stabilizing drug that gained
attention in the 1980s as a potential teratogen. VPA exposure is highly correlated with autism;
as many as 60% of infants who exhibit the suite of symptoms associated with VPA teratoge‐
nicity also display two or more autistic characteristics (Moore et al., 2000). Autism has also
been shown to occur in 9% of cases of prenatal exposure to VPA (Rasalam et. al., 2005). The
mechanisms underlying the pharmacological actions of VPA are also suggestive of a correla‐
tion between VPA and ASDs (Shimshoni et al., 2007). VPA is responsible for inhibiting two
enzymes: myo-inositol-1-phosphate (MIP) synthase and the class 1 and 2 histone deacetylase
Epigenetics and Epigenomics106
(HDAC). HDAC1 is an important inhibitor of DNA transcription that works by associating
with the LEC/TCF transcription factor. When HDAC1 is removed from the LEC/TCF complex,
it leaves behind a primed (but inactive) promoter of gene transcription. The primed promoter
then forms a complex with β-catenin, thus activating the promoter, and increasing transcrip‐
tion rates of a variety of genes in the wingless-type, mouse mammary tumor virus (MMTV)
integration site family, in the type 1 (Wnt) signaling pathway including cyclin D1, as well as
in those required for the transition from the G1 to S phases of mitosis. Additionally, the removal
of HDAC1 causes the an increase in the transcription rate of MYC, which is a transcription
enhancer for many genes throughout the genome (Billin et al., 2000). Accordingly, the
consequence of VPA-mediated inhibition of HDAC1 is to upregulate the transcription of Wnt
pathway genes. In addition, VPA increases cellular levels of β-catenin, presumably in response
to the increased availability of primed LEC/TCF promoters (Wang et al., 2010). The effect of
VPA on Wnt gene transcription is well understood but fails to explain the connection between
VPA and autism. In order to complete this link, it is necessary to note that an increase in the
number of neocortical minicolumns is highly correlated with autism (Williams and Casanova,
2010). This observation is supported by fMRI studies that report differences in how autism
brains coordinate the processing of information (Minshew and Williams, 2007). It is reasonable
to assume that processes which upregulate genes of the Wnt signaling pathway - such as
prenatal exposure to VPA - may result in poorly regulated mitosis and cellular proliferation,
one manifestation of which could be an increase in the number of neocortical minicolumns
and macrocephaly. This mechanism has been observed at work in a slightly different context.
Recall that Mecp2 inactivates genes by forming complexes with a variety of different mole‐
cules. One of these molecules is HDAC1 (Nan et al., 1998) and in the absence of HDAC1, or
even when HDAC1 has merely been downregulated, the gene inactivating properties of Mecp2
will be expected to have a diminished effect. One of the promoters on which Mecp2 typically
exerts its regulatory effect is the LEC/TCF promoter, which, as mentioned previously, ulti‐
mately regulates the transcription rates of the Wnt signaling pathway. Although Mecp2 has
effects on gene methylation, the function of HDAC1 concerns acetylation of histones. However,
in order for a gene to be transcriptionally deactivated, they must often be both methylated and
deacetylated. Thus, VPA-induced inhibition of HDAC1 interferes with the functionality of
Mecp2 which appears to increase the risk of developing ASD.
7.2. Exposure to sex steroids and antidepressants
Endocrine disruption early in pregnancy during sex-related differentiation of the brain
suggests several mechanisms for the development of ASD. Sex steroids are known to be potent
inhibitors of 3(17) alpha-hydroxysteroid dehydrogenase (AKR1C1), a bifunctional enzyme
that catalyzes the oxidoreduction of the 2- and 17-hydroxy/keto groups of sex steroid hor‐
mones, the main metabolite of which is epitestosterone. Epitestosterone is a sex steroid
produced in the mammalian brain, including that of humans. Epitestosterone is also shown
to occur in higher concentrations in females than in males and could be an important central
nervous system epigenetic regulator of gene expression that might help explain some of the
male predominance of ASDs. Epitestosterone metabolism may also be linked to the features
of ASDs associated with prenatal exposure to citrapolam, estradiol and valproic acid (Sanders,
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2012). Several in vitro studies show that sex steroids can also alter serotonin homeostasis and
mice expressing the common serotonin reuptake transporter (SERT) polymorphism, SERT
Ala56 – which is associated with increased serotonin clearance rates and plasma serotonin
concentrations and found in children with ASDs, (Dufour-Rainfray et al., 2010; Simpson et al.,
2011; Veenstra-Vanderweele et al., 2012). The serotonin reuptake inhibitor citrapolam (Celexa),
which increases plasma serotonin levels, is also implicated in heightened risk of ASDs in the
children born to mothers who were prescribed the drug in the early stages of their pregnancies
(Rai et al., 2013). These connections between sex steroids and serotonin homeostasis appear to
be complex, as evidenced by the finding that citrapolam exposure modulates both cerebral
cortical and noradrenergic locus coeruleus functions (previously discussed in relation to ASDs)
as well as produces autistic-like behaviors in male rats (Darling et al., 2011).
7.3. Prenatal exposure to organic environmental pollutants
ASDs have also been linked to perinatal exposure to a flame retardant chemical, pentabro‐
modiphenyl  ether,  BDE-47 (Woods et  al.,  2012).  BDE-47 is  one of  a  group of  chemicals
whose industrial production is required to be halted under the Stockholm Convention, a
treaty intended to protect against environment exposures to persistent organic pollutants.
Exposure  to  BDE-47  is  known to  negatively  impact  Mecp-2.  Mecp2 has  been discussed
previously in terms of the X chromosome-linked mutation that produces Rett syndrome, a
pervasive  autistic-like  neurodevelopmental  disorder  in  females.  Mecp2(308/+)  mice  are
knock-in  animal  models  shown to  exhibit  global  hypomethylation  of  adult  brain  DNA,
specifically in female offspring following perinatal exposure to BDE-47. This hypomethyla‐
tion is associated with decreased social interactions and decreased expression of DNMT3a,
a DNA methyltransferase required for learning and memory in hippocampus, specifically
in BDE-47-exposed Mecp2(308/+) offspring (Woods et al., 2012). Collectively, these results
demonstrate  that  some  chemical  environment-gene  interactions  relevant  to  social  and
cognitive behaviors exhibit sexual dimorphism and epigenetic dysregulation that are likely
relevant to the pathogenesis ASDs.
8. Other ASD-like diseases
8.1. Angelman syndrome
Epigenetic effects may also manifest through aberrant methylation patterns of imprinted
genes. The expression of imprinted genes, which are mostly found in clusters on chromosomes
6, 7, 11, 14 and 15, is controlled by a series of DNA methylations and histone modifications.
Imprinting defects may be primary or secondary. Primary imprinting defects cause changes
in observed methylation patterns, but leaves the DNA sequence unaltered, and thus may be
classified as an epigenetic mechanism (Gos, 2013). Angelman syndrome, which is caused by
an absence of active maternal genes in the 15q11-1q13 region, may result from a primary
imprinting defect, although the syndrome is more commonly caused by a deletion on the
maternal chromosome or a paternal uniparental disomy. There is some basis to suspect a link
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between Angelman syndrome and autism. For instance, in one particular study, though the
frequency of Angelman syndrome was only found to be 4 out of approximately 49,000, each
of those four children were found to demonstrate autistic behaviors. (Steffenburg et al., 1996).
However, other studies place the rate of co-occurrence of autism and Angelman syndrome at
a rate of as low as 2%. It seems reasonable to assert that, to the extent that Angelman syndrome
and autism are linked, the condition of some percentage of these patients will be related to an
epigenetic primary imprinting defect. However, the available evidence does not establish
whether the epigenetic defect causing Angelman syndrome leads directly to autistic symptoms
or whether the relationship between Angelman syndrome and autism are merely correlative,
and not causative.
8.2. Prader-Willi syndrome
On the other hand, secondary imprinting defects occur when a gene mutation results in
improper epigenetic regulation. Such a defect may occur in Prader-Willi syndrome, which is
characterized by the lack of a paternal contribution at the 15q11-q13 locus. The specific
mutation most commonly responsible for secondary imprinting in Prader-Willi syndrome is
a cis-acting defect of the imprinting regulatory center of the Prader-Willi syndrome gene
(Dykens, and Shah, 2003). Prader-Willi patients present with autistic behavior more frequently
than Angelman syndrome patients; studies suggest the frequency of autism co-occurrence
with Prader-Willi syndrome is between 18% and 38% (Veltman et al., 2004), though the
causative nature of this relationship has not been established.
8.3. Fragile X syndrome
Fragile X syndrome is the leading single-gene cause of autism accounting for as many at 5%
of all cases (McLennan et al., 2011). As with Prader-Willi and Angelman syndromes, epigenetic
mechanisms can contribute to the development of the Fragile X, which is characterized by the
presence of 200 or more CGG repeats in the 5' untranslated region of the FMR1 gene (Willemsen
et al., 2011). The resulting increased concentration of cytosine and guanine nucleotides causes
the global methylation of not only the CGG-repeat region but also adjacent regions, which
happen to include FMR1 promoter elements.
8.4. Rett syndrome
A missense mutation of the protein Mecp2 is known to produce Rett syndrome, a disease
formerly termed cerebral atrophic hyperammonemia, the signs and symptoms of which are
often confused with Angelman syndrome. Interestingly, hyperammonemia can also be
produced by urea cycle disorders and exposure to valproic acid (the latter being a known risk
factor for ASDs). Damage to the locus coeruleus-noradrenergic and midbrain dopaminergic
systems have been demonstrated and the etiology of Rett syndrome appears to be confirmed
by a study demonstrating that restoration of Mecp2 activity may be achieved by an IGF-1
treatment (Tropea et al., 2009).
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9. Role of epigenetic drift in autism
Earlier, we discussed investigations involving identical twins to elucidate the effects of the
intrauterine environment on the epigenome. As it happens, twin studies are also valuable
because they allow us to explore the concept of epigenetic drift. The idea of epigenetic drift
closely parallels the more familiar notion of genetic drift: Beginning with identical starting
conditions, epigenetic drift is the divergence of two formerly identical epigenomes in response
to external pressures. An investigation of global histone H3 and H4 acetylation, 5 methyl
cytosine methylation and X chromosome inactivation concluded that despite very few
differences between the epigenomes of monozygotic twins at birth, significant differences
between the epigenomes develop as the twins age (Fraga et al., 2005). Some studies have
indicated that epigenomic drift may occur on a scale two orders of magnitude more substantial
than genetic drift (Martin, 2012). Clearly, any number of factors - smoking, diet and physical
activity among them - may be responsible for these different changes. But it might also be the
case that an intermittent failure to properly transfer epigenetic information during the gene
replication process may play a role as well. In any event, regardless of the specific etiology of
the epigenomic changes, these are the sorts of heritable changes in methylation and acetylation
that we've previously seen to be linked to the development of ASDs in offspring.
10. Summary and conclusions
Figure 1 summarizes the main epigenetic mechanisms that appear to play roles in ASDs
include low activity of Mecp2 at CpG islands in genes of frontal cortex is shown to reduce the
capacity for inhibiting HDAC1 and chromatin condensation for gene silencing. HDAC1
inhibition by valproic acid and GSK3β inhibition by lithium are shown to upregulate the Wnt
signaling pathway, which in turn causes accumulation of β-catenin in the cytoplasm and its
translocation to the nucleus. In the nucleus β-catenin can act as an activator of transcription
and cause macrocephaly and the attendant increase in the number of cerebral cortical columns.
DNMT is shown to methylate the oxytocin receptor gene and silence it, resulting in the low
oxytocin and estrogen activity necessary for androgen receptor mediation of high arousal
inputs to the amygdyla. This defect is associated with antisocial behaviors after exposure to
environmental stressors. Histone H3 phosphorylation by protein kinase C beta is shown to
activate the LSD1, an HMT that prevents demethylation of H3K4, which is also necessary for
androgen receptor mediation of high arousal inputs to the amygdyla. Hypomethylation by
decreased availability of S-adenosyl methionine (SAM) is shown to occur in mothers of autistic
children. Environmental and nutritional conditions acting as pro- or anti-autism factors by
epigenetic mechanisms suggest strategies for decreasing the prevalence of ASDs. This
knowledge of putative epigenetic targets should motivate clinical practitioners and educators
to develop novel treatment strategies based on the environment-gene interactions which could































































































Figure 1. Main mechanisms of epigenetic alterations in autism. Each alteration involves many enzymes but the main
players to cause methylation or acetylation are shown by arrows. These are not separate mechanisms and the en‐
zymes do not act alone. Several enzymes act at a promoter simultaneously. 1. Low methyl CpG binding protein-2
(Mecp2) at CpG islands of frontal cortex reduces capacity for complexing with histone deacetylase 1 (HDAC1) for gene
silencing. 2. HDAC1 inhibition by valproic acid exposure and glycogen synthetase kinase-3B (GSK3B) inhibition by lithi‐
um upregulate Wnt signaling pathway, activates transcription, associated with macrocephaly with increased number
of cerebral cortical column. 3. DNA methyltransferase (DNMT) methylates oxytocin receptor gene produces low oxyto‐
cin and estrogen activity necessary for androgen receptor mediated high-arousal inputs to amygdala. 4. Histone H3
phosphorylation by protein kinase c beta activates the histone methyltransferase (HMT) lysine demethylase 1 (LSD1)
which prevents demethylation of lysine-4 site of histone-3 (H3K4) also necessary for androgen receptor (AR) media‐
tion of high arousal inputs to amygdala. 5. Maternal hypomethylation by dietary folic acid deficiency decreases availa‐
bility of S-adenosyl methionine (SAM), associated with abnormal intrauterine growth.
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